



Les GCO à l'ESMO 2020

19 - 23 septembre 2020

L'ESMO est le principal rendez-vous de la cancérologie au niveau européen au cours duquel sont partagés les résultats d'études cliniques sur le traitement des cancers. Les GCO présenteront leurs dernières études menées dans les cancers gynécologiques, digestifs, bronchiques ainsi que les cancers de la tête et du cou.

**9 communications orales (dont 1 en Symposium présidentiel),
9 mini-oral présentations et 11 E-posters, sur des essais promus ou
réalisés en collaboration avec l'un des membres des GCO.**

CANCERS DE LA TETE ET DU COU	p.2
CANCERS DIGESTIFS (COLORECTAUX ET NON COLORECTAUX)	p.3
CANCERS GYNECOLOGIQUES	p.3
CANCERS DU POUMON	p.4

MULTI-ORGANES

GCO-002 CACOVID-19 cohorte (promotion FFCD)

SARS- Cov-2 and cancer MINI ORAL SESSION

The GCO-002 CACOVID-19 cohort: a French nationwide multicenter study of COVID-19 infected cancer patients and consequences on cancer management

A. Lièvre

CANCERS DE LA TETE ET DU COU

GORTEC : Groupe Oncologie Radiothérapie Tête et Cou

Oral presentations

PembroRad (GORTEC 2015-01) : A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN)

Jean Bourhis

DEBIO 1143-201 (Debiopharm/Gortec) : A Phase I/II randomised study to determine the maximum tolerated dose, safety, pharmacokinetics and antitumor activity of Debio 1143 combined with concurrent chemo-radiation therapy in patients with locally advanced squamous cell carcinoma of the head and neck.

Jean Bourhis

CisFRAD (GORTEC 2015-02) : Comparison of Two Concomitant Administration of RT With Cisplatin in Standard Infusion or Fractional Infusion

Christian Borel

Topnivo (GORTEC/Unicancer) : A safety study of Nivolumab in Patients with Recurrent and/or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)

Jérôme Fayette

CANCERS DIGESTIFS (COLORECTAUX ET NON COLORECTAUX)

FFCD : Fédération Francophone de Cancérologie Digestive

Oral presentation

Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD phase III Trial: Second interim analysis

C. Lepage

E-posters

PRODIGE 25 (FFCD 11-01) - Phase II randomized trial evaluating aflibercept associated with LV5FU2 regimen as first line treatment of non-resectable metastatic colorectal cancers (FOLFA)

JL Legoux

Lanreotide as Maintenance Therapy After First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumours (NETs). An international double-blind, placebo-controlled randomized phase II.

C. Lepage

PRODIGE 71 - BEVAMAIN: A randomized phase III study comparing maintenance treatment with fluoropyrimidine + bevacizumab versus fluoropyrimidine after induction chemotherapy for a metastatic colorectal cancer.

T. Aparicio

FOLFIRINOX modified versus CISGEM chemotherapy for locally advanced, non resectable and/or metastatic biliary tract cancer AMEBICA: results of the phase II

JM Phelip

GERCOR : Groupe Coopérateur Multidisciplinaire en Oncologie

E-poster

Folfirinox relative dose intensity (RDI) and disease control in advanced pancreatic cancer patients (APC)

Antonin Vary

CANCERS GYNECOLOGIQUES

ARCAGY - Association de Recherche sur les CANCERS dont GYNécologiques

GINECO - Groupe d'Investigateurs Nationaux pour l'Étude des Cancers Ovariens et du sein

Oral presentation

Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase 3 trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)

Kathleen Moore

Mini oral sessions

Paclitaxel with or without pazopanib in ovarian cancer patients with relapse during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study

Florence Joly

Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian carcinoma (HGOC): final analysis of second progression-free survival (PFS2) in the Phase III PAOLA-1/ENGOT-ov25 trial

Antonio Gonzales

Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial

Nicoletta Colombo

Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial

Bhavana Pothuri

Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA (BRCAm): 5-year (y) follow-up (f/u) from SOLO1

Susana Banerjee

Efficacy of subsequent chemotherapy for patients (pts) with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO2/ENGOT Ov-21 trial

J-Sébastien Frenel

The impact of chemosensitivity assessed by modeled CA-125 KELIM on the likelihood of long progression-free survivorship (PS) after 1st line treatment in ovarian cancer: An analysis of 4,450 patients

Benoît You

AGO DESKTOP III/ENGOT OV20: Impact of surgical characteristics and time to first subsequent therapy (TFST)

Fabrice Lécuru

E-Posters

Extended follow-up of a real-world cohort of patients (pts) with BRCA mutation (BRCAm) relapsed epithelial ovarian cancer (EOC) receiving olaparib maintenance therapy: The GINECO RETROLA study.

Thibault de la Motte Rouge

Regorafenib (R) or tamoxifen (T) for platinum-sensitive recurrent ovarian cancer (PSROC) with rising CA125 and no evidence of clinical or radiological disease progression: A GINECO Randomized II trial

Olivier Trédan

ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor + palbociclib (AI+P) for metastatic breast cancer (MBC) in the PADA-1 trial

J-Sébastien Frenel

CANCERS DU POUMON

IFCT : Intergroupe Francophone en Cancérologie Thoracique

Oral presentations

PRESIDENTIAL SYMPOSIUM

An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement. Primary end-point analysis of Lung ART (IFCT-0503, UK NCRI, SAKK)

C. Le Pechoux

Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): preliminary results from a multicenter study (IFCT-1601 IONESCO)

M. Wislez

Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial

S. Peters

E-Posters

Lorlatinib for advanced ROS1+ Non-Small Cell Lung Cancer (NSCLC): efficacy and safety data from IFCT-1803 LORLATU Expanded Access Program (EAP) cohort

N. Girard

IFCT-1602 CHIVA2 phase II trial: Nivolumab in previously treated HIV-patients with advanced non-small cell lung cancer (NSCLC)

A. Lavolé

Autoimmune diseases in centrally reviewed Thymic Epithelial Tumors (TET)

JC. Benitez

Retrouvez tous les abstracts sur le site de l'ESMO en cliquant [ici](#)